Condition: NAFLD (Non-alcoholic Fatty Liver Disease) · Sponsor: Hinova Pharmaceuticals Inc.
Primary Objective: • To evaluate the efficacy of HP515 tablets in participants with non-alcoholic fatty liver disease. Secondary objectives: * To evaluate the safety of HP515 tablets in participants with non-alcoholic fatty liver disease; * To evaluate the pharmacokinetic of HP515 tablets in participants with non-alcoholic fatty liver disease; * To evaluate the pharmacodynamic effects of HP515 tablets in participants with non-alcoholic fatty liver disease; Exploratory objective: • To evaluate the impact of HP515 tablets on target markers in participants with non-alcoholic fatty liver disease. The study includes a screening period of 4 weeks, a treatment period of 12 weeks, and a safety follow-up period of 4 weeks.
This description comes directly from the study's public registry record.
Yang Ming YM Chief physician · +86-15810092973 · ymicecream@163.com
Wei WL chief physician · +86-15810092973 · weelai@163.com
Always discuss trial participation with your own doctor first.
| Beijing Tsinghua Changgung Hospital | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| Chengdu Seventh People's Hospital | Chengdu, Sichuan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07308548